CERO THERAPEUTICS HOLDINGS, INC.

Phoenix Biotech Acquisition Corp, listed on Nasdaq under the ticker PBAX and sponsored by Phoenix Biotech Sponsor, LLC, completed its initial public offering in 2021 with a focus on the biotechnology and life sciences sector. The blank-check company ultimately announced a business combination with Cero Therapeutics, a clinical-stage oncology firm developing chimeric engulfment receptor T-cell therapies targeting solid tumor indications. The 8-K filing dated October 31, 2022 was submitted under the combined entity name Cero Therapeutics Holdings, Inc., reflecting progress in the de-SPAC transaction process. Sign up at SpacDesk for complete filing history, deal timelines, and real-time data on PBAX and the broader SPAC market.